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INTRODUCTION
Despite improvements in early diagnosis, many patients
diagnosed with gastric cancer are inoperable at the time of
initial diagnosis. Even after intended curative resection, local,
regional, and distant recurrences develop in more than 80%
of patients. Advanced gastric carcinoma remains an incurable
disease with a median survival of 6 to 9 months. Two random-
ized trials have shown that a combination chemotherapy may
provide a significant survival benefit and offer an improved
quality of life to patients with the advanced gastric carcinoma
when compared with best supportive care (1, 2).
In the 1980s, the FAM (5-fluorouracil, doxorubicin, and
mitomycin-C) regimen was prematurely adopted as the stan-
dard therapy for advanced gastric cancer. However, a prospec-
tive randomized study later showed that the FAM regimen
had no survival benefit and more severe toxicity than single-
agent 5-fluorouracil (5-FU) treatment (3). One of the few
studies to show a small but significant survival benefit com-
pared FAMTX (5-FU, doxorubicin, and methotrexate) with
FAM, and the FAMTX was found to have higher response
rates (41% versus 9%) and longer duration of survival (42
vs 29 weeks) than FAM (4). 
5-FU given as a continuous intravenous infusion at a dose
of 300 mg/m2/day has been shown to elicit higher response
rates and less myelotoxicity than intermittent bolus admin-
istration in patients with colorectal cancer (5). The cumula-
tive overall response rate was 26% (95% confidence interval,
CI, 22% to 30%) for the infusional regimen and 10% (95%
CI, 6% to 14%) for the bolus arm, although no survival dif-
ferences were apparent. In addition to advanced colorectal
cancer, a protracted infusion of 5-FU resulted in a high re-
sponse rate (31%) in a small study of advanced gastric can-
cer (6). A regimen of epirubicin, cisplatin, and a protracted
infusion of 5-FU (ECF) was prescribed, based on the single-
agent activity of each agent in upper gastrointestinal cancer
and on the synergy between 5-FU and cisplatin already de-
monstrated in experimental models (7). In a randomized trial,
the addition of epirubicin to a combination of bolus 5-FU
and cisplatin resulted in a significant survival benefit com-
pared with 5-FU and cisplatin only in advanced gastric cancer
(8). In phase II studies with ECF, including the protracted
infusion of 5-FU, response rates of over 50% were reported,
with apparently moderate toxicity and satisfactory symptom
control (9-11). Moreover, the ECF regimen, including the
protracted infusion of 5-FU, resulted in a higher response
rate (45% vs 21%) and longer survival duration (8.9 months
vs 5.7 months) than FAMTX, with less myelosuppression,
less mucositis, and better quality of life in randomized trials
by Webb et al. and Waters et al. (12, 13). Therefore, we con-
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Epirubicin, Cisplatin, and Protracted Venous Infusion of 5-Fluorouracil
for Advanced Gastric Carcinoma
To evaluate the activity and safety of a combination chemotherapy with epirubicin,
cisplatin, and a protracted venous infusion of 5-fluorouracil (ECF) in unresectable
or metastatic gastric cancer, a phase II study was performed. Thirty-five chemo-
therapy-naive patients were given ECF. Epirubicin (50 mg/m
2 intravenous, IV) and
cisplatin (60 mg/m
2 IV) were administered every three weeks during a continu-
ous intravenous infusion of 5-fluorouracil (250 mg/m
2/day) using infusion pump.
One complete response and 19 partial responses (response rate=62%) were
achieved. Eight patients remained stable, whereas in four patients the disease
progressed. The median duration of response was 22 weeks (95% confidence
interval, 18-27 weeks). The median survival for all patients was 10 months (95%
confidence interval, 6-14 months), with a 1-yr survival rate of 40%. A total of 184
cycles of chemotherapy were administered. Grade 3 or 4 emesis occurred in 3%,
mucositis in 2%, anemia in 10%, and leukopenia in 3% of the cycles. Central
venous catheter complications that required line removal occurred in 37% (n=13)
of the patients. No patient died of toxicity. Overall, the ECF regimen showed high
anti-tumor activity with a tolerable toxicity pattern. 
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Accepted : 19 February 2002ducted a phase II study to confirm the activity and feasibili-
ty of an ECF regimen, including a protracted infusion of 5-
FU, in patients with metastatic gastric cancer. 
MATERIALS AND METHODS
Eligibility criteria
Patients enrolled in this study were required to fulfill the
following eligibility criteria: (1) histologically proven adeno-
carcinoma of the stomach with measurable metastatic lesions;
(2) an unresectable tumor, locally advanced, metastatic, or
relapsed after resection; (3) aged 70 yr or younger; (4) no pre-
vious chemotherapy or radiation therapy, though prior adju-
vant chemotherapy was allowed (>6 months apart); (5) East-
ern Cooperative Oncology Group scale performance status
of 2 or less; (6) adequate bone marrow (WBC ≥4,000/ L,
platelet ≥100,000/ L), liver (serum bilirubin level ≤2.0
mg/dL and serum transaminase level ≤100 IU/dL ), and
renal (serum creatinine level ≤1.5 mg/dL) functions; (7)
normal cardiac function; (8) no other severe medical condi-
tion; (9) a life expectancy of at least 3 months; and (10) must
have given written informed consent before being enrolled
in the study.
Treatment schedule
Chemotherapy was administered through a central venous
catheter placed in the subclavian vein. 5-FU was given as
continuous intravenous (IV) infusion at a dose of 250 mg/m2/
day using a portable pump (I-Flow Corporation, California,
U.S.A.). Epirubicin (50 mg/m2 IV) and cisplatin (60 mg/m2
IV infusion with adequate hydration) were given on Day 1
every 3 weeks to a maximum of nine cycles. Central venous
catheters were changed every 3 cycles to prevent catheter-
related complications. Granisetron was used routinely before
administration of cisplatin as a prophylactic antiemetics. 
Toxicity assessment and dose modifications
Toxicity was graded according to the National Cancer Insti-
tute (NCI) common toxicity criteria version 2.0. For patients
with Grade 3 or 4 non-hematologic toxicity, ECF adminis-
tration was interrupted until symptoms had resolved and
then restarted with a 25% dose reduction for Grade 3 toxicity
and a 50% dose reduction for Grade 4. Patients developing
hand-foot skin reactions were given 50 mg of pyridoxine
three times daily. If symptoms failed to improve, 5-FU was
discontinued for 1 week and restarted with a 25% dose reduc-
tion for Grade 3 toxicity. Cisplatin was administered at full
dose when the glomerular filtration rate (GFR) was equal to
or greater than 60 mL/min; if the GFR was 40-60 mL/min,
the dose of cisplatin in milligram equaled the GFR value in
milliliters per minute. No cisplatin was administered when
the GFR value was less than 40 mL/min.
If the leukocytes count was less than 3,000/ L or platelets
were less than 100,000/ L on the first day of treatment, ECF
administration was delayed for 1 week or until myelosuppres-
sion resolved. A second episode of treatment delay due to my-
elosuppression or an episode of neutropenic sepsis required a
25% dose reduction of 5-FU and epirubicin on subsequent
treatments. If there were repeated episodes of Grade 3 or 4
toxicity in spite of dose modification, the treatment was stop-
ped.
Superficial infection of the indwelling catheter was treated
with antibiotics according to bacteriological results. Indwell-
ing catheters were removed in the following situations: sep-
ticemia due to catheter infection, catheter infection worsen-
ing despite appropriate antibiotic treatment, catheter throm-
bosis, intolerable shoulder pain.
Assessment of response and statistical analysis
Before entering the study, all patients received a physical
examination, a complete blood count analysis, serum chem-
istry analysis, a chest radiography, an electrocardiogram, and
an abdominal computed tomographic scan with endoscopy.
The primary objectives of this study were to determine the
response rate and the toxicity of the ECF regimen. The sec-
ondary objectives were to evaluate the survival rate and the
duration of response of the regimen.
Objective response to chemotherapy in measurable lesions
was evaluated using the standard World Health Organization
criteria. In addition to the WHO criteria, histologic confir-
mation of endoscopic findings was required to classify a re-
sponse at the primary site as complete, and only measurable
lesions were considered assessable for response evaluation.
Time to progression was measured in all patients from the
beginning of chemotherapy to the first evidence of progres-
sion; duration of response was calculated in responding pa-
tients from the first evidence of response to the date of pro-
gression or death; duration of survival was calculated from
the beginning of treatment until the date of death. Curves
were plotted using the Kaplan-Meier method and compared
using the log rank test.
RESULTS
Characteristics of the patients
Thirty-five patients were enrolled in the study from May
1999 to March 2001. Thirty-two were assessable for response
and thirty-five for toxicity. Two patients were lost to follow-
up after the second cycle and before the first evaluation of re-
sponse. One patient experienced Grade 3 mucositis after the
first cycle and refused further therapy. Characteristics of the
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gastric cancer patients was 56 yr (range 36-68). Metastatic
sites were lymph node (n=28), peritoneum (n=9), liver (n=8),
adrenal gland (n=2), lung (n=1), and others (n=5). Patients
with peritoneal metastasis had other measurable metastatic
lesions. Thirty-four patients had had no previous chemothe-
rapy. One patient had received adjuvant chemotherapy with
5-FU and mitomycin for 6 months, 2 yr prior to the ECF
chemotherapy. 
Tumor response
Objective responses were seen in 20 of 32 (62%) patients,
with one patient (3%) achieving a complete response and 19
(59%) showing partial responses. Eight patients remained
stable, whereas four progressed. Median response duration
(Fig. 1) and time to progression were 22 weeks (95% CI, 18
to 27 weeks) and 25 weeks (95% CI, 18 to 32 weeks), re-
spectively. Median survival for all patients was 10 months
(95% CI, 6 to 14 months), with a 1-yr survival rate of 40%
(Fig. 2). 
Toxicity
A total of 184 cycles were delivered, with a median of 6
cycles per patient (range, 1-9 cycles). Overall, 92% of the
planned epirubicin dose was administered per course, 93%
of the planned 5-FU dose, and 94% of the planned cisplatin
dose, although dose reductions were required in 23 patients
(65%). 
Toxicity is shown in Table 2. Grade 3 or 4 emesis occurred
in 3%, mucositis in 2%, anemia in 10%, and leukopenia in
3% of the cycles. Treatment was delayed due to myelosup-
pression in 13 (7%) of the 184 cycles. Central venous catheter
complications requiring line removal occurred in 37% (n=13)
of the patients. Other catheter-related complications were
shoulder pain (n=10), infection (n=7), thrombosis (n=2), line
slippage (n=2), and pneumothorax (n=2). No complication
was life-threatening or resulted in a long-term morbidity. 
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Age (yr)       Median (range)           56 (36-68)
Sex                 Male                  28 (80)
Female                 7 (20)
Performance status  ECOG 0-1              28 (80)
2                7 (20)
Extent of disease  Locally advancecd       8 (23)
Metastatic              25 (71)
Relapse                 2 (6)
Metastatic site     Lymph Node             28 (
Peritonium              9 (
Liver                   8 (
Adrenal gland          2 (
Lung                   1 (
Others                 5 (
Prior chemotherapy No                     34 (
Yes                    1 (
Characteristics                                    No. (%)
Table 1. Patient characteristics
Hematologic                   
Leukopenia      58 (32)      36 (20)      4 (2) 2 (1)
Anemia                 62 (34)       44 (24)       16 (9)  2 (1)
Thrombocytopenia      12 (7)         4 (2)        1 (0.5) -
Nonhematologic
Nausea                  76 (41)        78 (42)       6 (3) -
Vomiting                29 (16)        24 (13)       4 (2)  1 (0.5)
Mucositis               17 (9)         13 (7)       4 (2)   -
Diarrhea                8 (4)         2 (1)        1 (0.5)      -
Neuropathy*            12 (34) 7 (20)   -        -
Hair loss*               24 (69)        9 (26)        -          -
Hand-foot skin reaction* 6 (17)        3 (9)         -          -
Total                                   184 cycles
Table 2. Toxic reactions
1 Grade (%)  2 3 4
*Maximum toxicity experienced by each patient (%).
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Fig. 1. Duration of response of responsive patients in advanced
gastric cancer. 
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Fig. 2. Overall survival of all patients in advanced gastric cancer.DISCUSSION
Patients with unresectable gastric cancers have an extremely
poor prognosis, with 5-yr survival rates ranging from 5% to
15%. Numerous attempts have been made to develop more
effective combination chemotherapy regimens using known
active drugs. The FAM regimen became the preferred treat-
ment in the 1980s. A FAM variant, which incorporates a high-
dose methotrexate instead of mitomycin (FAMTX), was her-
alded as having impressive activity. In a direct comparison
with FAM, FAMTX proved to be significantly superior in
terms of response rate (41% vs 9%; p=0.0001) and median
survival duration (9.7 months vs 6.7 months; p=0.004), and
was demonstrated to have acceptable toxicity (4). The activ-
ity of cisplatin as a single agent in gastric cancer, and evidence
that in combination with etoposide it might may be helpful
in overcoming multidrug resistance, led to the development
of a new combination regimen with increased response rates
but considerable toxicity (14). Specifically, in a randomized
comparison with FAMTX, etoposide, doxorubicin, and cis-
platin (EAP) was found to be no more active, and significant-
ly more toxic (15).
ECF, including a protracted infusion of 5-FU, showed high
response rates and median survival durations with tolerable
toxicity in phase II trials (9-11). The response rates of this
regimen, in studies by Findlay et al. (9), Zaniboni et al. (10),
and Bamias et al. (11), were 71%, 56%, and 61%, median
survival durations were 8.2 months, 9+ months, and 8.4
months, and treatment-related mortalities were 4.3%, 0%,
and 2.5%, respectively. Because these works reported low
toxicities, we used a higher dose of the protracted 5-FU infu-
sion (250 mg/ m2/day) than had been used in the other stud-
ies (200 mg/m2/day) in the hope of obtaining better respons-
es; however, toxic reactions and responses did not increase.
The majority of toxic reactions in our study were Grade 1-
2, and no one died of toxicity. The response rate (62%) and
median survival duration (10 months) in our study were sim-
ilar to those of the above-mentioned three studies. However,
complete remission rate was lower than reported previously
(3% vs 12%, 15%, and 11%). This discrepant result might
be due to differences in the inclusion criteria or to the vari-
able criteria used to interpret complete response, i.e., based
on CT scans or endoscopy of the primary lesion. 
The prolonged intravenous administration of 5-FU offers
two main advantages when compared with a bolus schedule:
a greater dose intensity and a better pharmacologic match to
the indolent cell kinetics characteristic of most human solid
tumors. Several randomized trials comparing the protracted
infusional 5-FU regimen versus a standard bolus arm have
demonstrated that a protracted infusion of 5-FU has result-
ed in a high response rate in advanced colorectal or gastric
cancer. Experimental data strongly suggest that continuous
exposure to 5-FU provides a superior antimetabolic effect in
terms of thymidylate synthase inhibition in human gastric
cancer specimens (16). Anthracyclines are known to be active
in gastric cancer, and epirubicin was incorporated into the
regimen as it is less likely to cause mucositis and cardiac tox-
icity than doxorubicin. Cisplatin infused with 5-FU in pre-
clinical studies showed synergistic activity due to the cis-
platin-induced deletion of intercellular methionine, which
results in enhanced binding of fluorodeoxyuridine monopho-
sphate to thymidylate synthase (17).
Despite higher response rates and lower toxicity, a poten-
tial drawback of ECF may be the poor patient acceptability
of the indwelling catheter and presence of the external infu-
sion pump. The most frequent central venous catheter com-
plication was shoulder pain, which disappeared two or three
days after catheter insertion in some of the patients; however,
in a few cases the catheter was removed due to pain. Other
complications were catheter infection, catheter slippage,
thrombosis, and pneumothorax. Central venous catheter com-
plications requiring line removal developed in 37% (n=13)
of patients. Thus, new methods that maintain a constant con-
centration of 5-FU in the blood without the use of a catheter
have been developed. Prodrugs of 5-FU such as UFT or capeci-
tabine can maintain a constant 5-FU level through long-term
oral administration. A phase II trial of epirubicin, cisplatin,
UFT, and leucovorin including oral uracil and tegafur instead
of 5-FU showed a 57.5% response rate and 15 months medi-
an survival duration (18). A clinical study on an oral capeci-
tabine-based combination regimen, instead of continuous
infusion to achieve a constant 5-FU level in blood, was also
reported. Capecitabine and cisplatin combination chemo-
therapy showed a 51% response rate and a median time to
progression of 144 days with acceptable toxicity (19).
The routine use of palliative chemotherapy in patients with
advanced gastric cancer remains controversial. The use of
chemotherapy in advanced gastric cancer is justified in select-
ed patients, e.g., in younger patients with a good performance
status, low tumor burden, and no other serious medical con-
dition, after adequately informing patients of potential gains
and risks (20). A new agent that is more active and less toxic is
required. In a phase II trial, docetaxel, irinotecan, and pacli-
taxel as single agents showed response rates of 24%, 18%,
and 17-23%, respectively, in previously untreated advanced
gastric cancer patients (21-23). It is likely that these agents
will be further evaluated as candidate agents for new combi-
nation chemotherapy regimens. 
In conclusion, the ECF regimen is very active and well tol-
erated in advanced gastric carcinoma. This regimen could
be studied in a postoperative adjuvant setting to improve
survival in gastric carcinoma. New methods or drugs should
also be developed to solve catheter-related problems.
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